Atlas Trials

Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients

Clinical trial NCT07235176 · RECRUITING

Trial details

NCT number
NCT07235176
Sponsor
Qilu Pharmaceutical Co., Ltd.
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Advanced ER+/HER2- Breast Cancer
Start date
2026-01-16
Primary completion
2028-11-02
Enrollment
300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.